Type 2 drug does not increase heart events
Dulaglutide does not increase the risk of major cardiovascular (CV) events in people with type 2 diabetes, research has found.
The meta-analysis evaluated the CV risk in people with the condition who were treated with Dulaglutide in nine randomised safety and efficacy trials.
Research was carried out because people with type 2 diabetes have a “substantial increased risk” for CV disease and associated mortality than those without it.
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist that is approved for treatment of type 2 diabetes.
Of the 6,010 people who took part in the research, 3,885 were taking Dulaglutide and the remaining 2,125 participants were given placebos.
The demographic and baseline CV disease characteristics were similar across groups, according to the paper.
The results of the study, Cardiovascular Safety for Once-Weekly Dulaglutide in Type 2 Diabetes, showed 26 people in the Dulaglutide group versus 25 in the comparator group experienced a primary 4-component MACE (HR 0.57; adjusted 98.02 per cent CI 0.30, 1.10).
Results for the 3-component MACE (composite endpoint of death due to CV causes, nonfatal MI or stroke), 6-component MACE (composite endpoint of death due to CV causes, nonfatal MI or stroke, hospitalisation for unstable angina or heart failure, or coronary revascularizations) and all-cause mortality were consistent with the primary analysis (HR < 1.0 for all).
The ongoing CV outcomes study, Researching CV Events with a Weekly Incretin in Diabetes (REWIND), will further assess CV safety of Dulaglutide.